Vericel to Present at 28th Annual Piper Jaffray Healthcare Conference
November 22 2016 - 8:30AM
Vericel Corporation (Nasdaq:VCEL), a leading developer of
autologous expanded cell therapies for the treatment of patients
with serious diseases and conditions, today announced that Nick
Colangelo, president and CEO, will present at the 28th Annual
Piper Jaffray Healthcare Conference at the Lotte New York Palace in
New York City, NY on Wednesday, November 30, 2016, at 1:00pm
Eastern time.
The presentation will be webcast live and may be accessed from
the news and events section of the Vericel
website: www.vcel.com/events.
About Vericel Corporation
Vericel develops, manufactures, and markets autologous expanded
cell therapies for the treatment of patients with serious diseases
and conditions. The company markets two cell therapy products
in the United States. Carticel® (autologous cultured
chondrocytes) is an autologous chondrocyte implant for the
treatment of cartilage defects in the knee in patients who have had
an inadequate response to a prior arthroscopic or other surgical
repair procedure. Epicel® (cultured epidermal autografts) is
a permanent skin replacement for the treatment of patients with
deep dermal or full thickness burns greater than or equal to 30% of
total body surface area. Vericel is also developing two
additional cell products. MACI® (autologous cultured
chondrocytes on porcine collagen membrane) is a third generation
autologous chondrocyte implant intended to treat cartilage defects
in the knee. Ixmyelocel T is an autologous multicellular
therapy intended to treat advanced heart failure due to ischemic
dilated cardiomyopathy (DCM). For more information, please
visit the company's website at www.vcel.com.
Epicel®, Carticel®, and MACI® are registered trademarks of
Vericel Corporation. © Vericel Corporation. All rights
reserved.
CONTACT:
Chad Rubin
The Trout Group
crubin@troutgroup.com
(646) 378-2947
or
Lee Stern
The Trout Group
lstern@troutgroup.com
(646) 378-2922
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Apr 2023 to Apr 2024